


Acting Administrator Enomoto
Page 2 of 2
May 26, 2016

rule does not address the many reasons cited by our members as to why they are not prescribing MAT to the fullest extent of their current waiver. We have heard concerns about governmental and third party reimbursement for the additional reporting, documentation, counseling and other requirements to prescribe MAT, concerns about the on-site DEA inspections, as well as the challenges of access to the counseling services in many rural and underserved communities necessary to meet the requirements of MAT prescribing.

Thank you for this opportunity to comment on this important public health initiative. If you have questions about these comments, please contact AAFP Senior Government Relations Representative, [Teresa Baker](#) at 202-232-9033.

Sincerely,

A handwritten signature in black ink that reads "Robert Wergin MD". The signature is written in a cursive style.

Robert Wergin, MD, FAAFP
Board Chair

cc: JinheeLee, PharmD [email: WaiverRegulations@samhsa.hhs.gov]